Physician profile
Mindi S Hudson
NPI 1821405663
$6,459.74
in general payments reported to CMS, 2019-2025
30 companies · $1,633 in 2025
The $1,633 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,074 · 2022: $973 · 2023: $1,304 · 2024: $1,474 · 2025: $1,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,370 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,369.51 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,101.49 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,008.23 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $648.78 | 2021-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $531.91 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $495.13 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $367.03 | 2021-2025 | |
| Pfizer INC. | $316.94 | 2021-2025 | |
| Glaxosmithkline, LLC. | $288.14 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.05 | 2021-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $198.28 | 2021-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $196.57 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $137.41 | 2023-2025 | Caplyta |
| Mannkind Corporation | $114.74 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $107.14 | 2021-2024 | Eliquis |
| Xeris Pharmaceuticals, INC. | $94.27 | 2022-2025 | Gvoke Hypopen |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $91.49 | 2023-2024 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $79.15 | 2021-2023 | |
| Astellas Pharma US INC | $71.29 | 2023-2025 | Veozah |
| Abbott Laboratories | $64.07 | 2021-2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $52.88 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $48.07 | 2021 | |
| Amarin Pharma, INC. | $41.92 | 2021 | |
| Insulet Corporation | $33.36 | 2024-2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $29.24 | 2021-2022 | |
| Exact Sciences Corporation | $28.71 | 2025 | The Cologuard Plus Collection Kit |
| Inspire Medical Systems, INC. | $23.47 | 2025 | Inspire |
| Nevro Corp. | $22.43 | 2023 | Senza |
| Verona Pharma, INC. | $20.40 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $19.54 | 2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $14.61 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mindi Hudson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.